inflammatory bowel disease

News

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

News

Boehringer signs €1bn+ deal for Simcere IBD candidate

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

A person putting wooden puzzle pieces together above grass

Abivax climbs on Lilly takeover speculation

Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.

News

OMass attracts $420m Roche wager on IBD programme

UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.

News

Vedanta's microbiome therapy for IBD disappoints

Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.

News

J&J adds to IL-23 options in Crohn's after FDA approval

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

MSD and Mayo Clinic team up on AI drug discovery

Boehringer signs €1bn+ deal for Simcere IBD candidate

Abivax climbs on Lilly takeover speculation

OMass attracts $420m Roche wager on IBD programme

Vedanta's microbiome therapy for IBD disappoints

J&J adds to IL-23 options in Crohn's after FDA approval

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

inflammatory bowel disease

Editor's Picks